About us

RMI Partners is a venture company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas.

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.

RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.

The Russian pharmaceutical company NovaMedica is a key company in RusNanoMedInvest’s portfolio. With NovaMedica, RMI promotes the transfer of know-how and intellectual property rights to its portfolio companies’ developments to Russia, in order to implement and promote them in the Russian market. NovaMedica’s strategy targets the research, registration and Russian localization of intellectual property rights for innovative products and technologies, the development and implementation of its own R&D projects, as well as the creation of a modern R&D center and high-tech pharmaceutical GMP production. 

RMI Partners is a member of Invest Europe, the association which is representing Europe’s private equity, venture capital and infrastructure sectors. 


News

  • 23 March 2017

    Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

    Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.